Sareum Hldgs Plc (SAR) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.763x

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has a cash flow conversion efficiency ratio of -0.763x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-1.74 Million ≈ $-2.33 Million USD) by net assets (£2.28 Million ≈ $3.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sareum Hldgs Plc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Sareum Hldgs Plc - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sareum Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sareum Hldgs Plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Cubic Digital Technology Co Ltd
SHE:300344
-0.061x
Mirae ING Co Ltd
KO:007120
0.028x
Ropharma Bras
RO:RPH
0.057x
Mount Ridley Mines Ltd
AU:MRD
-0.269x
Generic Engineering Construction and Projects Limited
NSE:GENCON
0.063x
Enero Group Ltd
AU:EGG
0.009x
Formosa Ingredient Factory PT Tbk
JK:BOBA
0.041x
SynCore Biotechnology Co Ltd
TWO:4192
-0.028x

Annual Cash Flow Conversion Efficiency for Sareum Hldgs Plc (2004–2025)

The table below shows the annual cash flow conversion efficiency of Sareum Hldgs Plc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Sareum Hldgs Plc stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 £2.28 Million
≈ $3.06 Million
£-2.55 Million
≈ $-3.43 Million
-1.120x +39.57%
2024-06-30 £2.11 Million
≈ $2.84 Million
£-3.92 Million
≈ $-5.26 Million
-1.854x +34.57%
2023-06-30 £1.15 Million
≈ $1.55 Million
£-3.27 Million
≈ $-4.39 Million
-2.833x -475.87%
2022-06-30 £4.33 Million
≈ $5.82 Million
£-2.13 Million
≈ $-2.86 Million
-0.492x +12.44%
2021-06-30 £2.80 Million
≈ $3.75 Million
£-1.57 Million
≈ $-2.11 Million
-0.562x -24.65%
2020-06-30 £1.80 Million
≈ $2.42 Million
£-813.09K
≈ $-1.09 Million
-0.451x +60.95%
2019-06-30 £1.09 Million
≈ $1.47 Million
£-1.26 Million
≈ $-1.70 Million
-1.154x -18.37%
2018-06-30 £1.63 Million
≈ $2.19 Million
£-1.59 Million
≈ $-2.14 Million
-0.975x -371.10%
2017-06-30 £2.35 Million
≈ $3.15 Million
£843.87K
≈ $1.13 Million
0.360x +198.88%
2016-06-30 £1.86 Million
≈ $2.50 Million
£-678.00K
≈ $-910.50K
-0.364x -5.22%
2015-06-30 £1.86 Million
≈ $2.50 Million
£-644.24K
≈ $-865.15K
-0.346x +24.16%
2014-06-30 £1.72 Million
≈ $2.31 Million
£-785.34K
≈ $-1.05 Million
-0.456x +65.64%
2013-06-30 £439.10K
≈ $589.67K
£-582.74K
≈ $-782.57K
-1.327x -5.88%
2012-06-30 £480.38K
≈ $645.10K
£-602.14K
≈ $-808.62K
-1.253x -100.37%
2011-06-30 £876.00K
≈ $1.18 Million
£-548.00K
≈ $-735.91K
-0.626x +37.68%
2010-06-30 £523.00K
≈ $702.34K
£-525.00K
≈ $-705.03K
-1.004x +54.03%
2009-06-30 £327.00K
≈ $439.13K
£-714.00K
≈ $-958.84K
-2.183x -81.42%
2008-06-30 £1.40 Million
≈ $1.88 Million
£-1.69 Million
≈ $-2.26 Million
-1.204x -579.37%
2007-06-30 £1.37 Million
≈ $1.83 Million
£-242.00K
≈ $-324.98K
-0.177x +13.59%
2006-06-30 £1.20 Million
≈ $1.60 Million
£-245.00K
≈ $-329.01K
-0.205x +82.42%
2005-06-30 £1.32 Million
≈ $1.77 Million
£-1.54 Million
≈ $-2.07 Million
-1.166x -2128.90%
2004-06-30 £-87.00K
≈ $-116.83K
£-5.00K
≈ $-6.71K
0.057x --

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$3.99 Billion
£2.97 Billion GBP
Market Cap Rank
#24608 Global
#232 in UK
Share Price
£21.50
Change (1 day)
-2.27%
52-Week Range
£12.00 - £27.50
All Time High
£457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more